Payment overview · 2025
General Payments
$211.59
10 reported records · 5 companies
Healthcare provider profile · identity verified
Dean Horacio Trantham
Allopathic & Osteopathic Physicians|Family Medicine · EASLEY, SC · NPI 1740778513
Verified facts
What the public records show
CMS Open Payments records show Dean Horacio Trantham received $211.59 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.59 | 31.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.76 | 26.4% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $41.42 | 19.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.74 | 15.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.08 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $211.59 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.76 | 3 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $41.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.30 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 77 |
| Lisinopril | Lisinopril | 250 | 73 |
| Omeprazole | Omeprazole | 233 | 72 |
| Metformin Hcl | Metformin Hcl | 228 | 63 |
| Gabapentin | Gabapentin | 193 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 56 |
| Montelukast Sodium | Montelukast Sodium | 162 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 45 |
| Losartan Potassium | Losartan Potassium | 137 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 44 |
| Lorazepam | Lorazepam | 117 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 24 |
| Clonazepam | Clonazepam | 98 | 16 |
| Trazodone Hcl | Trazodone Hcl | 93 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 22 |
| Tramadol Hcl | Tramadol Hcl | 68 | 22 |
| Carvedilol | Carvedilol | 65 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 21 |
| Potassium Chloride | Potassium Chloride | 62 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 21 |
| Glipizide Er | Glipizide | 57 | 14 |
| Famotidine | Famotidine | 56 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 16 |
| Allopurinol | Allopurinol | 55 | 15 |
| Ozempic | Semaglutide | 54 | 14 |
| Linzess | Linaclotide | 53 | suppressed |
| Meloxicam | Meloxicam | 53 | 17 |
| Metformin Hcl Er | Metformin Hcl | 53 | 20 |
| Bupropion Xl | Bupropion Hcl | 52 | 18 |
| Eliquis | Apixaban | 52 | 11 |
| Ezetimibe | Ezetimibe | 52 | 20 |
| Farxiga | Dapagliflozin Propanediol | 52 | 12 |
| Mirtazapine | Mirtazapine | 51 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 20 |
| Memantine Hcl | Memantine Hcl | 49 | 11 |
| Diazepam | Diazepam | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Prednisone | Prednisone | 40 | 23 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Furosemide | Furosemide | 38 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | 15 |
| Methylprednisolone | Methylprednisolone | 35 | 32 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 16 |
| Temazepam | Temazepam | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | 12 |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 13 |
| Azithromycin | Azithromycin | 32 | 26 |
| Simvastatin | Simvastatin | 32 | suppressed |
| Valsartan | Valsartan | 32 | 12 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | 12 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Finasteride | Finasteride | 28 | 14 |
| Fluconazole | Fluconazole | 27 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Glipizide | Glipizide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 14 | 12 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $211.59 · 10 records | ABBVIE INC. | AREXVY, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, Tresiba, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error